It simplifies income-driven repayment, but some borrowers might have to wait longer for forgiveness ...
(RTTNews) - Rapport Therapeutics, Inc. (RAPP) said the U.S. FDA has cleared the company to advance RAP-219 into registrational trials, allowing accelerated initiation of its Phase 3 program in focal ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results